Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice.
about
MicroRNA-regulated viral vectors for gene therapyAAV-mediated gene therapy for heart failure: enhancing contractility and calcium handlingRescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transferThe potential of adeno-associated viral vectors for gene delivery to muscle tissue.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disordersA single intravenous AAV9 injection mediates bilateral gene transfer to the adult mouse retina.Pompe disease gene therapy.MicroRNAs in cardiovascular disease.AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe miceInput-specific regulation of hippocampal circuit maturation by non-muscle myosin IIB.Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.Reengineering a transmembrane protein to treat muscular dystrophy using exon skippingApplication of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors.Gene therapy for the treatment of heart failure: promise postponedEnhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression.Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease.Adeno-associated virus-mediated gene therapy for metabolic myopathy.Modification of cardiovascular ion channels by gene therapy.Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus.Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo.Targeted gene therapy for the treatment of heart failure.Cardiac applications of optogenetics.Current Methods in Cardiac Gene Therapy: Overview.Copackaging of multiple adeno-associated viral vectors in a single production step.A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapyTargeting transgene to the heart and liver with AAV9 by different promoters.Successful transfection of genes using AAV-2/9 vector in swine coronary and peripheral arteries.microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors.Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice.Restoring heart function and electrical integrity: closing the circuit.Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth.
P2860
Q26745822-32702DFD-1290-4324-B054-B48D76F4ADE5Q28297096-97CD6962-CF3A-4CDF-BB05-38F11EF60265Q30515514-4140FB41-2688-4425-A3EC-32F7748D5BBBQ33902499-8BE662FC-5FA0-4333-B926-8E504402530FQ34205620-6F10AAB5-24E4-4D6D-A287-1175A8A1C5D3Q34684652-7DC00FF5-76A1-41C0-AC90-8AA194E072D2Q34982843-6DA98BB5-BEB5-471C-B7F7-4D659CD3866FQ34988737-8C1D9EDF-A93D-4FBD-B922-AE89C68DC98AQ35238264-01BAF036-BA45-4B1D-89F5-A196F31394B3Q35651103-14EB1CA2-0468-4294-94AF-A48A86D8E8B0Q35832885-E83C14CA-FA3A-4D67-A22A-1502206CE5C1Q36164927-926B14C9-D2AC-404E-AB17-43EEEBD0D749Q36266510-99EC12A2-3513-4C36-BD70-5B451144D6D3Q36883822-4D7180AB-F7F3-4654-9335-18027766413FQ36953151-D9F42F14-0684-4D83-86E0-3CA57092982CQ37122371-070EE44C-9F1F-4B7D-8AE9-942B820C575BQ37181416-96B2A3A1-ED0A-4368-A892-DB10223CA038Q37272261-43121CCA-E12B-4BC0-A516-1C49C94C9468Q37578556-B528BDBC-8958-4405-9A50-4012A5641AD4Q37615161-E5526EE1-C1A2-4728-9765-40170FCE698BQ37684597-3F500933-25B1-4A5E-9E44-09619D208A4BQ37720225-8012747C-DF44-48ED-83FC-038C78CFD785Q37878086-B61AF93C-9E63-40E3-ABAA-0E1CCD864DF3Q38230888-48A25A02-3AA8-4BC5-A702-C2E2FC7A7612Q38788217-63F958A5-19F5-4338-925A-CEB8199C4998Q38964154-233F7A90-3147-4706-9F5A-E8DACCA006C1Q39737661-A7AB9760-6F46-4699-B822-A14996E9F93AQ40516718-E92968B1-C1F2-4E2B-B696-B95FA2B968AFQ40738027-398F551D-13A4-4114-80D7-9265B80D578BQ41822591-3F0EBC7F-C877-4724-98C5-C32D6810EB62Q43703662-43FC3F28-66CC-4093-BB48-08A2A5182783Q46389336-1D8E33D6-010E-460D-9644-8004ABAE8C72Q52687520-ABE766EC-CA3A-45C1-A611-20FA5CE83189Q54262478-B2AD1E17-8B73-4477-B231-3FE37770E137
P2860
Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Tissue specific promoters impr ...... ene delivery in neonatal mice.
@en
type
label
Tissue specific promoters impr ...... ene delivery in neonatal mice.
@en
prefLabel
Tissue specific promoters impr ...... ene delivery in neonatal mice.
@en
P2093
P2860
P356
P1476
Tissue specific promoters impr ...... gene delivery in neonatal mice
@en
P2093
Barry J Byrne
Cathryn S Mah
Christina A Pacak
Yoshihisa Sakai
P2860
P2888
P356
10.1186/1479-0556-6-13
P577
2008-09-23T00:00:00Z
P5875
P6179
1004391494